Pricing Log in Create free account
Friday 6 November 2026 Export BGMS’s income statement to Excel — free account

Bio Green Med Solution, Inc.

BGMS Industrials Building Products & Equipment

Bio Green Med Solution, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747,000.00, up 1,637.2% from fiscal 2024.

Revenue
+3,260.0%
EPS
+91.8%
Free cash flow
+66.7%

Quarter to June 2026, against a year earlier

0.86 0.01 −1.15%
Market cap
$5.7M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
0.00%
F-score
4/9
Altman Z
−78.86
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 13.37%

Capital & Financial Ratios $m

Size
Market Cap 5.73
Revenue ttm 1.86
Net income ttm (2.20)
Free cash flow ttm (1.10)
Net debt Q (3.79)
Valuation
P/E 0.00
Forward P/E (0.34) (negative: loss-making)
Price / sales 2.62
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.68
Financial health
Current ratio Q 8.63 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 0.00
Growth
Revenue growth Q +3,260.00% (above 0%: growing)
Operating income growth Q +66.53% (above 0%: growing)
EPS, this year +92.71% (at or above 15%: strong)
EPS, next year A +39.49% (at or above 15%: strong)
Revenue, next year A −86.61% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.6×, against a ten-year median of −4.0×; over the ten years it ranged from −21.6× in 2022 to 284× in 2025.
P/S against its own 10 years 1.53%
10-year low 10-year high
P/B against its own 10 years 36.19%
10-year low 10-year high
EV/Sales against its own 10 years 6.17%
10-year low 10-year high

Dividends

Yield
0.00%
Annual rate
0.00
Payout ratio
—
Growth, 2016–25
0.00%/yr
  1. 0.15 ’16
  2. 0.00 ’17 −100
  3. 0.00 ’19
  4. 0.00 ’20
  5. 0.00 ’21
  6. 0.00 ’22
  7. 0.00 ’23
  8. 0.15 ’25
paid change on the year, %

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 3 3 4 4
Receivables — — 1 1
Inventory — — 1 1
Other — — — —
7 4 6 6
2023 2024 2025 Q'26
Payables 4 5 1 0
ST’ Debt — — — —
Other — — — —
8 6 1 1

Compound Annual Growth %

10y 5y 3y
Sales — (17.41%) 70.77%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (9.63%) (27.11%) (24.56%)

EPS $

Mar Jun Sep Dec Year
’26 (0.04) (0.08) — — —
’25 (0.22) (0.98) (1.31) (1.99) (6.45)
’24 (34.03) (172.71) (43.18) (77.62) (501.35)
’23 (1.69k) (1.58k) (114.20) (1.49k) (6.42k)
’22 (1.51k) (1.65k) (1.51k) (2.16k) (6.83k)
’21 (1.80k) (2.01k) (1.94k) (1.94k) (7.70k)
’20 (5.32k) (2.09k) (1.69k) (4.82k) (12.31k)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 1 0 — — —
’25 — — 0 1 1
’24 0 0 0 — 0
’23 — 0 0 0 0
’18 — — — — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 (3) (1) 0 0 (5)
’24 0 (3) (3) (1) (8)
’23 (7) (1) (4) (4) (16)
’22 (7) (2) (7) (5) (21)
’21 (4) (4) (6) (5) (19)
’20 (3) (2) (2) (1) (8)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 (3) (1) 0 0 (5)
’24 0 (3) (3) (1) (8)
’23 (7) (1) (4) (4) (16)
’22 (7) (2) (7) (5) (21)
’21 (4) (4) (6) (5) (19)
’20 (3) (2) (2) (1) (8)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1 — 0 — — — — 0 0 1 2 (1.3%) 0 — — (86.6%)
Gross margin, % 100.00 0.00 100.00 0.00 0.00 0.00 0.00 100.00 100.00 18.47 19.34 (81.5) pt
EBT (14) (8) (9) (9) (10) (22) (26) (26) (12) (3) 2 (15.6%)
EBT margin, % (1,633.93) 0.00 (5,750.00) 0.00 0.00 0.00 0.00 (6,083.57) (27,893.02) (400.40) 102.10 +1,233.5 pt
Net income (12) (7) (7) (8) (8) (18) (21) (23) (11) (3) (2) (14.1%)
Per share, $
Per share, $ Revenue 0.00 0.00 892.86 0.00 0.00 0.00 0.00 118.48 1.93 0.34 0.33 n/m
Earnings (251,748.20) (140,400.00) (44,595.39) (39,560.43) (12,312.00) (7,696.30) (6,833.17) (6,419.18) (501.35) (6.45) (3.42) (69.1%)
Cash flow 0.00 (70,566.04) (39,886.90) (47,235.00) (7,863.23) (7,416.00) (6,660.38) (4,544.99) (358.30) (2.18) (0.20) n/m
Capex 0.00 (122.64) (232.14) 140.00 (95.14) (10.80) (2.24) (1.69) 0.00 0.00 0.00 n/m
Free cash flow 0.00 (70,688.68) (40,119.05) (47,095.00) (7,958.37) (7,426.80) (6,662.62) (4,546.69) (358.30) (2.18) (0.20) n/m
Book value 0.00 205,339.62 90,904.76 58,485.00 32,962.34 15,077.20 5,097.22 171.23 (97.49) 3.13 1.28 n/m
Shares, m 0 0 0 0 0 0 0 0 0 2 5 n/m
Valuation, ×
Valuation, × P/E 0.00 — 0.00 — — — — 0.00 0.00 0.00 0.00 0.0
P/S 0.00 — 10.33 — — — — 3.19 47.95 9.92 2.62 14.3
P/B 0.00 — 0.57 — — — — 3.67 0.00 1.10 0.68 1.1
EV/Sales (19.60) — (10.43) — — — — (1.65) 5.55 5.32 0.58 (4.2)
EV/FCF 1.65 — 1.32 — — — — 0.07 (0.05) (0.86) (1.08) 0.4
Cash, $m
Cash, $m Operating cash flow (10) (7) (7) (9) (8) (19) (21) (16) (8) (5) (1) (8.0%)
Capex 0 0 0 0 0 0 0 0 — — 0 n/m
Free cash flow (10) (7) (7) (9) (8) (19) (21) (16) (8) (5) (1) (8.0%)
Balance, $m
Balance, $m Working capital 14 22 15 12 33 36 17 (1) (3) 5 5 (11.2%)
Net debt (17) (24) (18) (12) (33) (37) (18) (3) (3) (4) (4) (15.8%)
Shareholders’ equity 14 22 15 12 33 38 16 1 (2) 7 7 (7.8%)
Returns, %
Returns, % ROA (53.98) (65.02) (32.68) (45.72) (47.67) (46.68) (60.12) (123.49) (173.84) (229.53) (217.30) (175.5) pt
ROIC 0.00 0.00 0.00 0.00 0.00 (1,233.96) 0.00 0.00 0.00 (157.83) (67.28) (157.8) pt
ROE (72.44) (82.39) (40.44) (59.56) (55.26) (52.59) (79.80) (275.06) 1,431.01 (603.77) (246.85) (531.3) pt
People
People Employees 13 12 14 12 12 12 12 8 6 19 — +4.3%
Revenue/emp, $m 0.06 0.00 0.01 0.00 0.00 0.00 0.00 0.05 0.01 0.04 — (5.4%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Bio Green Med Solution, Inc. vs peers in Building Products & Equipment (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AEHL Antelope Enterprise Holdings L $331.6M — (loss-making) — +475.97% (above 0%: growing) n/m +10.99% (above 0%: growing) 15.26% 0.00% Compare
PPIH Perma-Pipe International Holdings, Inc. $223.0M 14.2× 19.3× +24.35% (above 0%: growing) +181.82% (above 0%: growing) +216.09% (above 0%: growing) 29.22% 7.14% Compare
AIRJ AirJoule Technologies Corporation $157.9M — (loss-making) — — n/m +36.98% (above 0%: growing) — 0.00% Compare
JLHL Julong Holding Limited $142.0M — — — — — — — Compare
JELD JELD-WEN Holding, Inc. $87.6M — (loss-making) — (loss-making) −1.36% (below 0%: shrinking) n/m +262.03% (above 0%: growing) 17.23% 1.10% Compare
INVE Identiv, Inc. $60.8M — (loss-making) — (loss-making) +12.72% (above 0%: growing) n/m −32.64% (below 0%: shrinking) 16.12% (97.01%) Compare
CSTE Caesarstone Ltd. $44.3M — (loss-making) — (loss-making) −4.52% (below 0%: shrinking) n/m +111.99% (above 0%: growing) 24.01% (10.60%) Compare
BGMS Bio Green Med Solution, Inc. $5.7M — (loss-making) — (loss-making) +3,260.00% (above 0%: growing) n/m +66.67% (above 0%: growing) 23.51% (124.40%)
ILAG Intelligent Living Application Group Inc. $3.7M — (loss-making) — −62.74% (below 0%: shrinking) n/m +46.20% (above 0%: growing) (5.69%) 0.00% Compare
Median of peers $114.8M — — +5.68% — +46.20% 16.68% 0.00%

All 34 Building Products & Equipment stocks →

Pay and ownership Proxy statement filed 27 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2024 585.00k 547.71k 3.76
2023 661.05k 65.81k 26.69

Ownership

Directors and executive officers, together 23.75%
Datuk Dr. Doris Wong Sing Ee 20.13%
Yap Kim Choy 8.47%
Fitters Diversified Berhad 5.06%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Bio Green Med Solution, Inc. (BGMS) Latest News

12 Aug

Impact 3 ·

4 Jun

Impact 4 · · GlobeNewswire

14 May

Impact 3 · · GlobeNewswire

30 Mar

Impact 4 · · GlobeNewswire

13 Nov

Impact 4 · · GlobeNewswire
Impact 3 · · GlobeNewswireGuruFocus.comGuruFocus.comMotley FoolGuruFocus.comMotley FoolGuruFocus.comMotley Fool

13 Aug

Impact 3 ·

4 Aug

Impact 4 · · GlobeNewswire

16 Jul

Impact 3 ·

7 Jul

Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire

2 Jul

Impact 3 · · GlobeNewswire

20 Jun

Impact 3 · · GlobeNewswire

2 Apr

Impact 3 ·

24 Mar

Impact 3 · · GlobeNewswire

27 Feb

Impact 4 · · GlobeNewswire

3 Jan

Impact 4 ·

5 Dec

Impact 4 · · GlobeNewswire

15 Nov

Impact 3 · · Simply Wall St.

12 Nov

Impact 4 · · GlobeNewswire

23 Oct

Impact 4 · · GlobeNewswire

9 Oct

Impact 4 · · GlobeNewswire

25 Sep

Impact 4 · · GlobeNewswire

4 Sep

Impact 3 · · GlobeNewswire

3 Sep

Impact 3 · · GlobeNewswire

2 Sep

Impact 4 · · Zacks

18 Aug

Impact 3 · · Simply Wall St.

14 Aug

Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

7 Aug

Impact 3 · · GlobeNewswire
stockrow.com/BGMS · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com